People who take aspirin regularly over the long-term have a higher risk of developing age-related macular degeneration (AMD), the main cause of blindness among seniors, researchers from the University of Sydney, Australia, reported in JAMA Internal Med…
Aspirin Use Linked to Macular Degeneration (CME/CE)
(MedPage Today) — Regular aspirin use was associated with an elevated risk for neovascular age-related macular degeneration, an Australian study suggested, but actual causality remains uncertain.
Endothelin-1 is a transcriptional target of p53 in epidermal keratinocytes and regulates UV induced melanocyte homeostasis
By: arup.indra
Uncategorized
NETAG issues appraisal and recommendation on aflibercept for AMD
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose (Read more...)
Uncategorized
CHMP does not recommend idebenone (Raxone®) for the treatment of Leber’s hereditary optic neuropathy
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending the refusal of the marketing authorisation for the orphan medicine idebenone (Raxone®), intended for the treatment of patients with Leber’s hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight.
The company presented the results from one main randomised, placebo-controlled study involving 85 patients with LHON whose symptoms started in the previous five years. The main measure of effectiveness was the change in vision after (Read more...)
Uncategorized
CHMP recommends approval of ocriplasmin (Jetrea®) for vitreomacular traction
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for ocriplasmin (Jetrea®) for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ?400 microns. VMT is an age-related progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness. It is estimated to affect between 250,000 to 300,000 patients in Europe.
Ocriplasmin is a recombinant form of human plasmin, administered as a single intravitreal injection. It (Read more...)